852285-78-0

Upstream product

• 31680-08-7 4-methoxy-3-nitrobenzaldehyde 
• 61010-34-2 3-nitro-4-methoxybenzyl bromide 
• 41870-24-0 (4-methoxy-3-nitrophenyl)methanol 
• 119-10-8 4-methoxy-3-nitrotoluene 
• 22216-44-0 2-(4-methoxy-3-nitrobenzylthio)acetic acid 

Downstream Products

• 852283-23-9 (E)-1,3,5-trimethoxy-2-(2-(4-methoxy-3-nitrobenzylsulfinyl)vinyl)benzene 

Relevant academic research and scientific papers

Synthesis and biological evaluation of benzyl styrylsulfonyl derivatives as potent anticancer mitotic inhibitors

We herein report the synthesis, biological activity and structure activity relationship of derivatives of benzylstyrylsulfone, benzylstyrylsulfine and benzylsulfonyl-N-phenylacetamide. A lead compound 7 represents a new class of mitotic inhibitors that demonstrates potent anti-proliferative activity and selectively induces cancer cell apoptosis while sparing non-transformed lung fibroblast.

Design, synthesis and evaluation of 3-substituted coumarin derivatives as anti-inflammatory agents

Coumarin moiety has garnered momentous attention especially in the design of compounds with significant biological activities. In this work, a series of 3-substituted coumarin derivatives 6a-6l were synthesized and fully characterized. Most of the compoun

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl] phenylamino}acetate (ON 01910.Na): Synthesis, structure-activity relationship, and biological activity

Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer. Accordingly, there is an increasing awareness of this novel nonenzymatic target for cancer therapeutics. We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells. The development of derivatized styrylbenzylsulfones followed logically from a tumor cell cytotoxicity screen performed in our laboratory that did not have an a priori target profile. Modifications of some of the precursor molecules led to lead optimization with regard to tumor cell cytotoxicity. In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent sodium (E)-2-{2-methoxy-5-[(2′,4′,6′- trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na), which is in phase III trials for myelodysplastic syndromes (MDS) associated with aberrant expression of cyclin D proteins.

ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS

alphabeta-Unsaturated sulfoxides of Formula I: (I) are useful as antiproliferative agents including, for example, anticancer agents, and as radioprotective and chemoprotective agents.